Literature DB >> 12427904

N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects.

M J J Edwards1, I P Hargreaves, S J R Heales, S J Jones, V Ramachandran, K P Bhatia, S Sisodiya.   

Abstract

Serum glutathione levels were assessed in a patient with genetically proven Unverricht-Lundborg disease (ULD) before and during treatment with the antioxidant N-acetylcysteine (NAC). Glutathione levels were low before treatment, and increased during treatment. This increase was mirrored by an improvement in seizures, but not in myoclonus or ataxia. Three other patients with clinically determined ULD showed a variable response and some notable side effects during treatment with NAC.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12427904     DOI： 10.1212/wnl.59.9.1447

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  12 in total

1.  Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1.

Authors:  Maria K Lehtinen; Saara Tegelberg; Hyman Schipper; Haixiang Su; Hillel Zukor; Otto Manninen; Outi Kopra; Tarja Joensuu; Paula Hakala; Azad Bonni; Anna-Elina Lehesjoki
Journal:  J Neurosci       Date:  2009-05-06       Impact factor: 6.167

Review 2.  The ketogenic diet in a pill: is this possible?

Authors:  Jong M Rho; Raman Sankar
Journal:  Epilepsia       Date:  2008-11       Impact factor: 5.864

Review 3.  Role of oxidative stress in epileptic seizures.

Authors:  Eun-Joo Shin; Ji Hoon Jeong; Yoon Hee Chung; Won-Ki Kim; Kwang-Ho Ko; Jae-Hyung Bach; Jau-Shyong Hong; Yukio Yoneda; Hyoung-Chun Kim
Journal:  Neurochem Int       Date:  2011-06-13       Impact factor: 3.921

4.  N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG/Rij rat model of absence epilepsy.

Authors:  Martina Tallarico; Antonio Leo; Lorenza Guarnieri; Maria Caterina Zito; Carmen De Caro; Ferdinando Nicoletti; Emilio Russo; Andrew Constanti; Giovambattista De Sarro; Rita Citraro
Journal:  Mol Neurobiol       Date:  2022-02-15       Impact factor: 5.590

5.  Cystatin B and SOD1: protein–protein interaction and possible relation to neurodegeneration.

Authors:  Lisa Ulbrich; Mauro Cozzolino; Elettra Sara Marini; Ilaria Amori; Antonella De Jaco; Maria Teresa Carrì; Gabriella Augusti-Tocco
Journal:  Cell Mol Neurobiol       Date:  2014-03       Impact factor: 5.046

Review 6.  Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Amir Ghaderi; Anna Bussu; Catherine Tsang; Sadegh Jafarnejad
Journal:  Eur J Clin Pharmacol       Date:  2018-11-16       Impact factor: 2.953

7.  Antioxidants as a preventive treatment for epileptic process: a review of the current status.

Authors:  Boštjan Martinc; Iztok Grabnar; Tomaž Vovk
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

8.  Progressive myoclonic epilepsy type 1: Report of an Emirati family and literature review.

Authors:  Mohammed Saadah; Mahfoud El Beshari; Loai Saadah; Hisham Hamdallah; Zeinab Alloub; Amani Ali Al Zaabi; Abdelmatlob Ben-Mussa; Anwaar Ben-Nour
Journal:  Epilepsy Behav Case Rep       Date:  2014-05-04

9.  A Native Haitian Woman with Unverricht-Lundborg Disease.

Authors:  Maliheh Mohamadpour; Genevieve Gabriel; Arthur C Grant
Journal:  Case Rep Neurol       Date:  2017-12-11

Review 10.  Progressive myoclonic epilepsy.

Authors:  Mary L Zupanc; Benjamin Legros
Journal:  Cerebellum       Date:  2004       Impact factor: 3.648
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.